

## PO-278: Real-world experience of Galcanezumab in 101 patients with migraine and fibromyalgia. (Galca-Only Consortium)

Victor Obach<sup>1</sup>, Rocio Alvarez-Escudero<sup>2</sup>, Nuria Riesco<sup>2</sup>, Alba Bravo<sup>3</sup>, Marta Ruibal<sup>4</sup>, Ane Minguez<sup>4</sup>, Fernando Velasco<sup>5</sup>, Izaro Kortazar<sup>6</sup>, Amaya Echeverria<sup>6</sup>, Elisa Cuadrado<sup>7</sup>, Sonsoles Aranceta<sup>8</sup>, Santiago Fernandez-Fernandez<sup>1</sup>, Neus Fabregat<sup>1</sup>, Teresa Marco<sup>1</sup>, Juan Carlos Garcia-Monco<sup>9</sup>, Aintzine Ruisanchez<sup>10</sup>, David Garcia-Azorin<sup>11</sup>.

<sup>1</sup>Hospital Clinic, Barcelona, Spain. <sup>2</sup>Hospital Central de Asturias, Oviedo, Spain. <sup>3</sup>Hospital Reina Sofia, Tudela, Spain. <sup>4</sup>Hospital de Donosti, San Sebastian, Spain. <sup>5</sup>Hospital Cruces, Bilbao, Spain. <sup>6</sup>Hospital Txagorritxu, Alava, Spain. <sup>7</sup>Hospital del Mar, Barcelona, Spain. <sup>8</sup>Hospital Tauli, Sabadell, Spain. <sup>9</sup>Hospital de Basurto, Bilbao, Spain. <sup>10</sup>Hospital Galdakao, Bilbao, Spain. <sup>11</sup>Hospital de Valladolid, Valladolid, Spain

### OBJECTIVE

To analyze tolerability and effectiveness of galcanezumab in patients with migraine and fibromyalgia.

### METHODS

The “Galca-Only Consortium” is a multicenter ambispective cohort study. All consecutive patients with chronic migraine or high-frequency episodic migraine with prior failure to three or more migraine preventive drugs, treated with galcanezumab were included.

Patients were systematically assessed by headache experts and followed up quarterly for 12 months.

Response to treatment was defined as the proportion of patients who achieved a reduction of at least 50% (R50) in the number of headache days per month, compared to the baseline period. Tolerability was assessed as the proportion of patients who discontinued the treatment due to inadequate tolerability. Data of follow-up at 12 months are presented.

In the present sub-analysis, patients with a diagnosis of fibromyalgia were compared with patients with no prior history of fibromyalgia.

### RESULTS

Study period: 15th November 2019 to 31st January 2022. Patients with fibromyalgia n=101 up to 880 patients' registry (11.5%).

Female gender, chronic migraine and higher frequency of monthly headache days per month were more frequent in patients with fibromyalgia.


At 12 month, the proportion of patients who achieved R50 was 32.7% in fibromyalgia and 52.1% in non-fibromyalgia group (p=0.001) and discontinuation of galcanezumab due to adverse events was 28.3% and 13,9% (p=0.01), respectively.

### CONCLUSION

One third of patients with fibromyalgia have a good response to galcanezumab.

**Table1.** Demographics of the study population.

	Fibromyalgia n=101	Non-Fibromyalgia n=779	P value
Age, mean (SD)	50.6 (11.0)	49.4 (12.3)	0.1
Female, n (%)	97 (96.0)	637 (81.8)	<b>0.001</b>
Migraine worsening, years [IQR]	8 [4-15]	8 [4-14]	0.2
Chronic migraine, n (%)	86 (85.0)	562 (72.1)	<b>0.001</b>
Mood disorders, n (%)	70 (69.3)	276 (35.4)	<b>0.001</b>
Monthly headache days, baseline [IQR]	27 [20-30]	20 [13-30]	<b>0.001</b>
HIT6 baseline [IQR]	72 [67-74]	68 [65-72]	0.2



**Figure 1.** Proportion of patients who achieved a 50% response